Global Neurocutaneous Disorder Market Size, Status and Forecast 2018-2025

Report / Search Code: RnM2375514     Publish Date: 30 August, 2018

Description:
This report focuses on the global Neurocutaneous Disorder status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neurocutaneous Disorder development in United States, Europe and China. Neurocutaneous Disorders are disorders that lead to growth of tumors in various parts of the body. They’re caused by the abnormal development of cells in an embryo and characterized by the tumors in various parts of the body (including the nervous system) and certain differences in the skin. While some can be diagnosed at birth, others don’t produce symptoms until later in life. Although neurocutaneous disorders can’t be cured, treatments can help manage symptoms and any health problems that occur.

Common neurocutaneous disorders that affect kids include neurofibromatosis, sturge-Weber syndrome, tuberous sclerosis (TS), ataxia-telangiectasia (A-T) and von Hippel-Lindau disease (VHL). Symptoms vary widely from condition to condition, and they affect different kids in different ways. Often, the full effects of these diseases — even if detected at birth — don’t emerge until a child grows up. The educational, social, and physical problems that the conditions cause must be managed throughout a child’s life.

In 2017, the global Neurocutaneous Disorder market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025. The key players covered in this study are:

- Valeant Pharmaceuticals
- Allergan
- Syneron Medical
- Medtronic
- Cutera
- St Jude Medical
- Pfizer

Market segment by Type, the product can be split into:
- Tuberous Sclerosis (TS)
- Neurofibromatosis (NF)
- Sturge-Weber Syndrome Disease
- Von Hippel-Lindau Disease (VHL)

Market segment by Application, split into:
- Hospital & Clinics
- Diagnostic Centers

Market segment by Regions/Countries, this report covers:
- United States
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America

The study objectives of this report are:
To analyze global Neurocutaneous Disorder status, future forecast, growth opportunity, key market and key players.
To present the Neurocutaneous Disorder development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Neurocutaneous Disorder are as follows:
- History Year: 2013-2017
- Base Year: 2017
- Estimated Year: 2018
- Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents:

1. Report Overview
   1.1 Study Scope
   1.2 Key Market Segments
   1.3 Players Covered
   1.4 Market Analysis by Type
      1.4.1 Global Neurocutaneous Disorder Market Size Growth Rate by Type (2013-2025)
      1.4.2 Tuberous Sclerosis (TS)
      1.4.3 Neurofibromatosis (NF)
      1.4.4 Sturge-Weber Syndrome Disease
      1.4.5 Von Hippel-Lindau Disease (VHL)
1.4.6 Ataxia-Telangiectasia (A-T)

1.5 Market by Application
1.5.1 Global Neurocutaneous Disorder Market Share by Application (2013-2025)
1.5.2 Hospital & Clinics
1.5.3 Diagnostic Centers
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Neurocutaneous Disorder Market Size
2.2 Neurocutaneous Disorder Growth Trends by Regions
2.2.1 Neurocutaneous Disorder Market Size by Regions (2013-2025)
2.2.2 Neurocutaneous Disorder Market Share by Regions (2013-2018)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Neurocutaneous Disorder Market Size by Manufacturers
3.1.1 Global Neurocutaneous Disorder Revenue by Manufacturers (2013-2018)
3.1.2 Global Neurocutaneous Disorder Revenue Market Share by Manufacturers (2013-2018)
3.1.3 Global Neurocutaneous Disorder Market Concentration Ratio (CR5 and HHI)
3.2 Neurocutaneous Disorder Key Players Head office and Area Served
3.3 Key Players Neurocutaneous Disorder Product/Solution/Service
3.4 Date of Enter into Neurocutaneous Disorder Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Neurocutaneous Disorder Market Size by Type (2013-2018)
4.2 Global Neurocutaneous Disorder Market Size by Application (2013-2018)

5 United States
5.1 United States Neurocutaneous Disorder Market Size (2013-2018)
5.2 Neurocutaneous Disorder Key Players in United States
5.3 United States Neurocutaneous Disorder Market Size by Type
5.4 United States Neurocutaneous Disorder Market Size by Application

6 Europe
6.1 Europe Neurocutaneous Disorder Market Size (2013-2018)
6.2 Neurocutaneous Disorder Key Players in Europe
6.3 Europe Neurocutaneous Disorder Market Size by Type
6.4 Europe Neurocutaneous Disorder Market Size by Application

7 China
7.1 China Neurocutaneous Disorder Market Size (2013-2018)
7.2 Neurocutaneous Disorder Key Players in China
7.3 China Neurocutaneous Disorder Market Size by Type
7.4 China Neurocutaneous Disorder Market Size by Application

8 Japan
8.1 Japan Neurocutaneous Disorder Market Size (2013-2018)
8.2 Neurocutaneous Disorder Key Players in Japan
8.3 Japan Neurocutaneous Disorder Market Size by Type
8.4 Japan Neurocutaneous Disorder Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Neurocutaneous Disorder Market Size (2013-2018)
9.2 Neurocutaneous Disorder Key Players in Southeast Asia
9.3 Southeast Asia Neurocutaneous Disorder Market Size by Type
9.4 Southeast Asia Neurocutaneous Disorder Market Size by Application

10 India
10.1 India Neurocutaneous Disorder Market Size (2013-2018)
10.2 Neurocutaneous Disorder Key Players in India
10.3 India Neurocutaneous Disorder Market Size by Type
10.4 India Neurocutaneous Disorder Market Size by Application

11 Central & South America
11.1 Central & South America Neurocutaneous Disorder Market Size (2013-2018)
11.2 Neurocutaneous Disorder Key Players in Central & South America
11.3 Central & South America Neurocutaneous Disorder Market Size by Type
11.4 Central & South America Neurocutaneous Disorder Market Size by Application

12 International Players Profiles
12.1 Valeant Pharmaceuticals
12.1.1 Valeant Pharmaceuticals Company Details
12.1.2 Company Description and Business Overview
12.1.3 Neurocutaneous Disorder Introduction
12.1.5 Valeant Pharmaceuticals Recent Development
12.2 Allergan
12.2.1 Allergan Company Details
12.2.2 Company Description and Business Overview
12.2.3 Neurocutaneous Disorder Introduction
12.2.4 Allergan Revenue in Neurocutaneous Disorder Business (2013-2018)
12.2.5 Allergan Recent Development
12.3 Syneron Medical
12.3.1 Syneron Medical Company Details
12.3.2 Company Description and Business Overview
12.3.3 Neurocutaneous Disorder Introduction
12.3.4 Syneron Medical Revenue in Neurocutaneous Disorder Business (2013-2018)
12.3.5 Syneron Medical Recent Development
12.4 Medtronic
12.4.1 Medtronic Company Details
12.4.2 Company Description and Business Overview
12.4.3 Neurocutaneous Disorder Introduction
12.4.4 Medtronic Revenue in Neurocutaneous Disorder Business (2013-2018)
12.4.5 Medtronic Recent Development
12.5 Cutera
12.5.1 Cutera Company Details
12.5.2 Company Description and Business Overview
12.5.3 Neurocutaneous Disorder Introduction
12.5.4 Cutera Revenue in Neurocutaneous Disorder Business (2013-2018)
12.5.5 Cutera Recent Development
12.6 St Jude Medical
12.6.1 St Jude Medical Company Details
12.6.2 Company Description and Business Overview
12.6.3 Neurocutaneous Disorder Introduction
12.6.4 St Jude Medical Revenue in Neurocutaneous Disorder Business (2013-2018)
12.6.5 St Jude Medical Recent Development
12.7 Pfizer
12.7.1 Pfizer Company Details
12.7.2 Company Description and Business Overview
12.7.3 Neurocutaneous Disorder Introduction
12.7.4 Pfizer Revenue in Neurocutaneous Disorder Business (2013-2018)
12.7.5 Pfizer Recent Development
13 Market Forecast 2018-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2018-2025)
13.10 Market Size Forecast by Application (2018-2025)
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details